Company: TYRA
Filing Date: 2025-05-08
Form Type: S-3
Source: 0001193125-25-116008
Chunk: 48

Company: Tyra Biosciences, Inc.
Filing Date: 2025-05-08
Form: S-3
Chunk 48
---
 and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than
$700.0 million measured on the last business day of our second fiscal quarter.

6

THE OFFERING

| Common stock offered by us                                  |     | Shares of our common stock having an aggregate offering price of up to $150.0 million.                                                                                                                                                |
| Common stock outstanding immediately following the offering |     | 68,089,957 shares, assuming sales of 15,000,000 shares in this offering at an assumed offering price of $10.00 per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on May 6,     
 2025. The actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur.                                                                       |
| Plan of Distribution                                        |     | “At the market offering” that may be made from time to time on the Nasdaq Global Select Market or other market for our common stock in the United States through or to TD Securities, as our sales agent or principal. See the        
 section entitled “Plan of Distribution” in this prospectus.                                                                                                                                                                           |
| Use of Proceeds                                             |     | We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and marketable securities, to fund the development of our product candidates and preclinical and drug discovery programs and 
 for working capital and general corporate purposes. See “Use of Proceeds.”                                                                                                                                                            |
| Risk Factors                                                |     | See the section titled “Risk Factors” on page 8 in this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully                 
 consider before deciding to invest in shares of our common stock.                                                                                                                                                                     |
| Nasdaq Global Select Market symbol                          |     | “TYRA”                                                                                                                                                                                                                                |

The number of shares of our common stock to be outstanding immediately after this offering is based on 53,089,957 shares of our common stock outstanding as of March 31, 2025. The number of shares outstanding as of March 31, 2025 excludes:

| • |